Role of FDG PET in the staging, recurrence and treatment response to imatinib (Glivec) in patients with gastrointestinal stromal tumors;Utilidad de la PET con FDG en el estudio de estadificación inicial, recurrencia y respuesta al tratamiento con imatinib (Glivec) en pacientes diagnosticados de un tumor del estroma gastrointestinal

Revista Espanola de Medicina Nuclear

Volumn 25, Issue 2, 2006, Pages 80-88

  Simo Perdigo M ^a   Garcia Garzon J R ^a   Soler Peter, M ^a   Perez Moure G ^a   Lopez Gandul S ^a   Lomena Caballero F J ^a  

^a CETIR Unitat PET   (Spain)

Author keywords

FDG PET; Gastrointestinal stromal tumors; Glivec; Positron emission tomography; Sarcoma

Indexed keywords

FLUORODEOXYGLUCOSE; IMATINIB;

ARTICLE; CAMERA; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HISTOCHEMISTRY; HUMAN; MALE; MESENTERY DISEASE; PERITONEAL DISEASE; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RADIODIAGNOSIS; TREATMENT RESPONSE; WHOLE BODY TOMOGRAPHY;

EID: 33646522729     PISSN: 02126982     EISSN: None     Source Type: Journal    
DOI: 10.1157/13086249     Document Type: Article

References (26)

1. Berman J, O'Leary TJ. Gastrointestinal stromal tumor workshop. Human Pathol. 2001;32:578-82.
2. Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol. 2000;15:1293-301.
3. Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol. 2000;7:705-12.
4. Burkill GJ, Badran M, Al-Muderis O, Meirion Thomas J, Judson IR, Fisher C, et al. Malignant gastrointestinal stromal tumors; distribution, imaging features and pattern of metastastic spread. Radiology. 2003;226:527-32.
5. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progresion-free-survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364:1127-34.
6. Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, et al. Safety and efficacy of Imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001;358:1421-3.
7. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-80.
8. Casado Herráez A. Impacto del uso del STI-571 en el tratamiento de tumores sólidos. Rev Oncol. 2003;5 Supl 2:28-36.
9. Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med. 2004; 45:357-65.
10. 18FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med. 2004;45:17-21.
11. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003;39:2012-20.
12. Gámez Cenzano C, Cabrera Villegas A, Sopena Monforte R, García Velloso MJ. La tomografía por emisión de positrones (PET) en oncología (Parte I). Rev Esp Med Nucl, 2002;21:41-60.
13. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, et al. Oncological applications of positron emission tomography with fluorine-18-fluorodeoxyglucose. Eur J Nucl Med. 1996;23:1641-74.
14. Warburg O. The metabolism of tumors. London: Constabel & Co; 1980.
15. Lomena Caballero FJ, Simo Perdigo M. Indications of PET imaging. Med Clin (Barc). 2003;120:742-9.
16. Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E, et al. The value of PET, CT and in-line PET/TC in patients with gastrointestinal stromal tumours: long term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging. 2005;32:153-62.
17. Hawkins RA, Hoh CK. PET FDG studies in oncology. Nucl Med and Biol. 1994;21:739-47.
18. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron emission tomography scanning: potential for error in interpretation. Semin Nucl Med. 1996;26:308-14.
19. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-82.
20. Valk PE, Abella-Columna E, Haseman MK, Pounds TR, Tesar RD, Myers RW, et al. Whole-body PET imaging with [18F] fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg. 1999;134:503-11.
21. 18FDG uptake in the differentiation of low-grade from high-grade brain tumours with PET. Radiology. 1995;195;47-52.
22. Gámez Cenzano C. Utilidad diagóstica de la tomografía de positrones en la evaluación de los gliomas. Revista de Oncología. 2000;2:3-11.
23. Rodríguez M, Rehn S, Ahlström H, Sundström C, Glimelius B. Predicting malignance grade with PET in non-Hodgkin's Lymphoma. J Nucl Med. 1995;36:1790-6.
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst. 2000;92:205-16.
25. Choi H, Faria SC, Benjamin RS, Podoloff DA, Macapinlac HA, Charnsangavej C. Monitoring treatment effects of STI-571 on gastrointestinal stromal tumours (GIST) with CT and PET: a quantitative análisis [abstract]. Radiology. 2002;225:583.
26. Van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato di Paola E, et al. Updated of phase I study of imatinib (STI5719) in advanced soft tissue sarcomas and gastrointestinal stroma tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002;38 Supl 5:S83-7.